<DOC>
	<DOCNO>NCT00706134</DOCNO>
	<brief_summary>This study evaluate efficacy safety aliskiren 75 mg , 150 mg , 300 mg elderly patient essential hypertension give light meal .</brief_summary>
	<brief_title>Efficacy Safety Aliskiren 75 mg , 150 mg , 300 mg Elderly Patients With Essential Hypertension When Given With Light Meal 8 Week Placebo-controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Male female outpatient 65 year age old . Patients eligible able participate study , consent purpose nature investigation clearly explain ( write inform consent ) . At randomization visit patient must office msSBP great equal 150 mmHg &lt; 180 mmHg ( msDBP &lt; 110 mmHg ) less equal 15 mmHg difference last two visit single blind runin period . Severe hypertension [ Office msDBP ≥110 mmHg and/or mean sit systolic blood pressure ( msSBP ) ≥ 180 mmHg ] . History evidence secondary form hypertension . Known KeithWagener grade III IV hypertensive retinopathy . History hypertensive encephalopathy cerebrovascular accident , include history transient ischemic cerebral attack ( TIA ) . Current diagnosis heart failure ( NYHA Class IIIV ) . History myocardial infarction , coronary bypass surgery , percutaneous coronary intervention ( PCI ) . Current angina pectoris require pharmacological therapy nitrate . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>≥ 65 year</keyword>
	<keyword>aliskiren</keyword>
	<keyword>placebo</keyword>
	<keyword>light meal</keyword>
</DOC>